Mesothelioma Prognosis

BAP1 gene mutations are linked to better mesothelioma outcomes and hereditary cancer risk. Learn how genetic testing in 2026 can guide treatment decisions and improve survival rates.

Brigham and Women's Hospital mesothelioma treatment program offers 51% 5-year survival rates through pioneering surgery, clinical trials, and multimodal care in Boston.

Compare EPP and P/D surgery for mesothelioma, understand survival rates, and learn about emerging surgical techniques. Expert guide to choosing the right procedure for your diagnosis.

Compare pleural mesothelioma (lung lining, 80% of cases) vs peritoneal mesothelioma (abdominal, 15-20%). Learn how location affects symptoms, treatment options, and survival rates.

Mesothelioma and lung cancer differ in 7 critical ways including cell origin, causes, treatment, and prognosis. Learn how correct diagnosis affects treatment and compensation.

FDA-approved immunotherapy drugs Keytruda and Opdivo are transforming mesothelioma treatment. Learn how checkpoint inhibitors work, who qualifies, and what results patients are seeing in 2026.

56+ active mesothelioma clinical trials offer access to breakthrough treatments in 2026. Learn about immunotherapy, CAR T-cell therapy, and targeted treatments that are quadrupling survival rates.

Current mesothelioma survival statistics by stage, cell type, and treatment approach. Understand prognosis factors and how modern treatments are improving outcomes.

Learn what your mesothelioma diagnosis means. Guide to 4 stages, 3 cell types, pleural vs peritoneal differences, and how these factors affect treatment options and prognosis.